scholarly journals The Effects ofHelicobacter pyloriEradication on Proteinuria in Patients with Primary Glomerulonephritis

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Bahar Caliskan ◽  
Halil Yazici ◽  
Yasar Caliskan ◽  
Yasemin Ozluk ◽  
Mine Gulluoglu ◽  
...  
Keyword(s):  
Iga Nephropathy ◽  
Eradication Therapy ◽  
Spontaneous Remission ◽  
Positive Staining ◽  
Stool Antigen Test ◽  
Protein Levels ◽  
Reactive Protein ◽  
Before And After ◽  
Stool Antigen ◽  
H Pylori

Background. Membranous nephropathy (MN) is a common cause of nephrotic syndrome. In most cases it is idiopathic, while it may also be secondary to many diseases. In this study, prevalence ofH. pyloriinfection and the effects ofH. pylorieradication on proteinuria levels were investigated.Methods. Thirty five patients with MN (19 male), 12 patients with IgA nephropathy (4 male) and 12 patients with focal segmental glomerulosclerosis (FSGS) (8 male) were studied. The presence ofH. pyloriantigen was investigated in renal tissues obtained by biopsy, and the effects ofH. pylorieradication on proteinuria levels were investigated.Results. Immunohistochemistry withH. pyloriantigen revealed no positive staining in the glomeruli of all patients. 19 patients (54%) with MN, 10 (83%) with IgA nephropathy and 4 (33%) with FSGS were positive forH. pyloristool antigen test(P=0.045). Patients withH. pyloriinfection were administered eradication therapy (lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days). Before the eradication therapy the mean proteinuria of patients with MN, IgA nephropathy and FSGS were 2.42 ± 3.24 g/day, 2.12 ± 1.63 g/day and 1.80 ± 1.32 g/day, respectively. Three months after eradication, baseline proteinuria levels of patients with MN significantly decreased to 1.26 ± 1.73 g/day(P=0.031). In all three groups there were no significant differences with regard to serum creatinine, albumin and C-reactive protein levels before and after eradication therapy.Conclusions. The eradication ofH. pyloriinfection may be effective to reduce proteinuria in patients with MN, while spontaneous remission of MN could not be excluded in this patient cohort. This trial is registered withNCT00983034.

A novel monoclonal stool antigen test for the detection of H. pylori before and after eradication therapy: A prospective study in outpatients

2003 ◽  
Vol 124 (4) ◽  
pp. A177 ◽  
Author(s):  
Vincens Weingart ◽  
Holger Ruessmann ◽  
Sibylle Koletzko ◽  
Josef Weingart ◽  
Wilhelm Hoechter ◽  
...  
Keyword(s):  
Prospective Study ◽  
Eradication Therapy ◽  
Antigen Test ◽  
Stool Antigen Test ◽  
Before And After ◽  
Stool Antigen ◽  
H Pylori ◽  
A Prospective Study

Evaluation of Rapid H. pylori Stool Antigen Test before and after Eradication Therapy

2005 ◽  
Vol 100 ◽  
pp. S69-S70 ◽  
Author(s):  
Akifumi Tanaka ◽  
Kengo Tokunaga ◽  
Kyoto Imase ◽  
Hajime Sugano ◽  
Hitoshi Ishida ◽  
...  
Keyword(s):  
Eradication Therapy ◽  
Antigen Test ◽  
Stool Antigen Test ◽  
Before And After ◽  
Stool Antigen ◽  
H Pylori

scholarly journals Impact of Helicobacter pylori Eradication Therapy on Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura

2015 ◽  
Vol 8 (7) ◽  
pp. 35 ◽  
Author(s):  
Mohamadreza Amiri
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Eradication Therapy ◽  
Current Treatment ◽  
Thrombocytopenic Purpura ◽  
Stool Antigen Test ◽  
Platelet Counts ◽  
Before And After ◽  
History Of ◽  
H Pylori

<p>This study was a before and after clinical evaluation of <em>Helicobacter pylori</em> eradication on platelet counts in a group of 23 patients with chronic Idiopathic (Autoimmune) thrombocytopenic purpura (CITP). <em>H. pylori </em>infection was identified in patients by a <sup>13</sup>C-urea breath test and confirmed by an <em>H. pylori</em> stool antigen test. Eradication was conducted in patients testing positive. Infected (<em>n</em> = 10) and uninfected (<em>n</em> = 13) patient groups did not differ with respect to age, gender, history of previous splenectomy, treatment with anti-D, current treatment with corticosteroids, or initial platelet count<strong>s</strong>. <em>H pylori</em> eradication was successful in eight infected CITP patients, with two patients not responsive to treatment. Compared to the uninfected group, patients in the infected group who responded to eradication therapy had significantly increased platelet counts after six months (56.2 ± 22.2 <em>vs.</em> 233 ± 85.6 ×10<sup>3</sup> million cells/L; <em>P </em>&lt; 0.01), whereas platelet counts in the non-responding patients and uninfected group did not differ after this period of time. <em>H. pylori</em> eradication promotes significant platelet count improvement in patients with CITP. Thus, all patients with CITP should be tested and treated for<em> H. pylori </em>infections.</p>

scholarly journals The Use of 13C-Urea Breath Test for Non-Invasive Diagnosis of Helicobacter pylori Infection in Comparison to Endoscopy and Stool Antigen Test

Diagnostics ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. 448
Author(s):  
Hamed Alzoubi ◽  
Asma’a Al-Mnayyis ◽  
Ibrahim Al rfoa ◽  
Amin Aqel ◽  
Mohammad Abu-Lubad ◽  
...  
Keyword(s):  
Breath Test ◽  
Eradication Therapy ◽  
Urea Breath Test ◽  
P Value ◽  
Antigen Test ◽  
Stool Antigen Test ◽  
Non Invasive ◽  
Stool Antigen ◽  
13C Urea Breath Test ◽  
H Pylori

Helicobacter pylori (H. pylori) can cause gastritis, peptic ulcer diseases and gastric carcinoma. Endoscopy as the gold standard method of diagnosis is an invasive procedure that might not be suitable in all scenarios. Therefore, this first study in Jordan aimed to assess the non-invasive 13C urea breath test (UBT) and stool antigen test for diagnosis of H. pylori infection and the successfulness of eradication therapy as alternatives for endoscopy. Hence, a total of 30 patients attending the endoscopy units at Alkarak teaching hospital were asked to complete a questionnaire with demographic and clinical data. They were then tested for H. pylori using 13C UBT and H. pylori stool antigen before having endoscopy. Another 30 patients who were positive for H. pylori by endoscopy were tested using both tests 6 weeks post eradication therapy. Results showed that the rate of H. pylori detection using endoscopy was 56.7% (17/30). Heartburns (82.3%, p value = 0.019), epigastric pain (88.2%, p value = 0.007) and vomiting (70.5%, p value = 0.02) were the most significant symptoms. Family history of peptic ulcer diseases was significantly associated with an increased risk for having a H. pylori positive result (p value = 0.02). Compared to endoscopy, the sensitivity of 13C UBT for the diagnosis of H. pylori was 94.1% (16/17), while it was 76.5% (13/17) for the stool antigen test. The specificity of both tests was equal (76.9%). However, the positive predictive and negative predictive values (84.2% and 90.9%) for 13C UBT were higher than those (81.3% and 71.4%) for the stool antigen test. The accuracy of 13C UBT was 86.7% compared to 76.7% for the stool antigen test. There was an 87% agreement (20 patients out of 23) between both tests when used to assess success of the eradication therapy. In conclusion, the 13C UBT was found to be more sensitive and accurate than the stool antigen test when used for diagnosis; furthermore, it has a comparable outcome to the stool antigen test in assessing the successfulness of the eradication treatment.

Comparison of the Neutrophil/Lymphocyte Ratio and C-Reactive Protein Levels in Patients With Amputation for Diabetic Foot Ulcers

2017 ◽  
Vol 16 (1) ◽  
pp. 23-28 ◽  
Author(s):  
Hasan Metineren ◽  
Turan Cihan Dülgeroğlu
Keyword(s):  
Diabetic Foot ◽  
Inflammatory Marker ◽  
Foot Ulcer ◽  
Diabetic Foot Ulcer ◽  
C Reactive Protein ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Protein Levels ◽  
Reactive Protein ◽  
Before And After

This study compared the effectiveness of the neutrophil/lymphocyte ratio (NLR) versus C-reactive protein (CRP) for evaluating the prognosis and degree of inflammation in patients with amputation for a diabetic foot ulcer (DFU). This study enrolled 56 patients with amputations for DFU with gangrene and compared the CRP levels and NLR measured before and after surgery. Overall, 24 patients (42%) died within 2 weeks postoperatively. Mortality increased with a preoperative/postoperative CRP difference ≤1.5 ( P < .001) and age 73 years or older ( P < .001). The postoperative NLR was lower than the preoperative value but was not significant as a prognostic or inflammatory marker ( P = .945). An increasing serum CRP level is a significant predictor of mortality. CRP and old age are reliable prognostic factors in patients with DFU.

scholarly journals Safety of meningococcal group B vaccination in hospitalised premature infants

2018 ◽  
Vol 104 (2) ◽  
pp. F171-F175 ◽  
Author(s):  
Alison Kent ◽  
Kazim Beebeejaun ◽  
Serena Braccio ◽  
Seilesh Kadambari ◽  
Paul Clarke ◽  
...  
Keyword(s):  
Adverse Events ◽  
Premature Infants ◽  
Antibiotic Use ◽  
Neurological Status ◽  
Serious Adverse Events ◽  
Historical Cohort ◽  
Protein Levels ◽  
Reactive Protein ◽  
Before And After ◽  
Group B

ObjectivesTo assess the risk of significant adverse events in premature infants receiving the novel 4-component group B meningococcal vaccine (4CMenB) with their routine immunisations at 2 months of age.Participants, design and settingIn December 2015, Public Health England requested neonatal units across England to voluntarily participate in a national audit; 19 units agreed to participate. Anonymised questionnaires were completed for infants receiving 4CMenB alongside their routine immunisations. For comparison, a historical cohort of premature infants receiving their primary immunisations without 4CMenB or paracetamol prophylaxis was used.Main outcome measuresParacetamol use; temperature, cardiovascular, respiratory and neurological status before and after vaccination; and management and investigations postvaccination, including serum C reactive protein levels, infection screens and antibiotic use.ResultsComplete questionnaires were returned for 133 premature infants (<35 weeks’ gestation) who received their first dose of 4CMenB at 8 weeks of age, including 108 who received prophylactic paracetamol according to national recommendations. Overall, 7% (8/108) of infants receiving 4CMenB with paracetamol had fever (>38°C) after vaccination compared with 20% (5/25) of those receiving 4CMenB without paracetamol (P=0.06) and none of those in the historical cohort. There were no significant differences between cohorts in the proportion of infants with apnoea, bradycardia, desaturation and receiving respiratory support after vaccination.Conclusions4CMenB does not increase the risk of serious adverse events in hospitalised premature infants. This audit supports the current national recommendations to offer 4CMenB with other routine vaccinations and prophylactic paracetamol to premature infants at their chronological age.

Sign in / Sign up

Export Citation Format

Share Document